BACE inhibitors, which decrease BACE1 (β-secretase) cleavage of the amyloid precursor protein (APP) and subsequently reduce neurotoxic amyloid-β (Aβ) levels, have been in clinical trials for the treatment of Alzheimer’s disease. This evidence concerns the gene BACE1 and early-onset autosomal dominant Alzheimer disease.